Skip to main navigation
Plx Pharma logo

Investor Relations

Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Plx Pharma logo Plx Pharma logo Plx Pharma logo Plx Pharma logo
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
  • Home
  • About Us
    • About Us
    • Our Story
    • Management Team
    • Scientific Advisory Board
    • Board of Directors
  • Our Technology
    • Our Technology
    • VazaloreTM
    • Pipeline
    • Publications
  • Investors
  • FAQS
  • Contact
Investor Menu
  • Overview
  • News Releases
  • Events & Presentations
    • Events
    • Presentations
  • Stock
    • Stock Quote & Chart
    • Historical Price Lookup
    • Analyst Coverage
  • Governance
    • Document & Charters
    • Committee Composition
  • Financials
    • SEC Filings
    • Financial Results
  • IR Resources
    • Investor FAQs
    • Email Alerts
    • Contact IR

Investor Relations

Corporate Profile

PLx Pharma Inc. is a commercial-stage drug delivery platform technology company focused on improving how and where active pharmaceutical ingredients (APIs) are absorbed in the gastrointestinal (GI) tract via its clinically validated and patent protected PLxGuard™ technology. PLx believes this platform has the potential to improve the absorption of many drugs currently on the market or in development, and to reduce the risk of stomach injury associated with certain drugs. To learn more about PLx Pharma Inc. and its pipeline, please visit www.plxpharma.com.

Stock Information

Exchange
Volume
Today's Open
Previous Close

Data Provided by Refinitiv. Minimum 15 minutes delayed.

  • View More
Recent News
20 May, 2022
PLx Pharma Inc. Showcases VAZALORE at The Annual Meeting of The Society for Cardiovascular Angiography and Interventions
VAZALORE Featured in Prominent Publication as Promising Alternative to Current Aspirin Options for Secondary Prevention of Cardiac Events SPARTA, N. J., May 20, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a commercial-stage drug delivery platform technology
Learn More
13 May, 2022
PLx Pharma Inc. Reports First Quarter 2022 Results and Provides Business Update
BUILDING A SOLID BASE OF VAZALORE ® USERS Total Net Sales of $2.1 Million in the First Quarter of 2022, an Increase of Approximately 31% from Fourth Quarter of 2021 GAAP Net Loss of ( $0.39 ) Per Diluted Share in the First Quarter 2022; Adjusted Non-GAAP Net Loss Per Diluted Share of ( $0.66 ) Cash
Learn More
22 April, 2022
PLx Pharma Inc. to Discuss 2022 First Quarter Financial Results on May 13, 2022 Conference Call and Provide Business Update
SPARTA, N.J. , April 22, 2022 (GLOBE NEWSWIRE) -- PLx Pharma Inc.  (NASDAQ: PLXP) (“PLx” or the “Company”) is a commercial-stage drug delivery platform technology company focused on its clinically-validated and patent-protected PLxGuard™ that has the potential to improve the absorption of many
Learn More
  • View More
Upcoming Events
More events are coming soon.
  • View More
  • Print Page
  • RSS Feeds
  • Email Alerts
Plx Pharma logo

Quick Links

  • Privacy Policy
  • Terms and Conditions
  • Site Map
  • Contact Us

Contacts

  • info@plxpharma.com
  • (973) 409-6541
  • (973) 843-6300
  • 9 Fishers Lane, Suite E
    Sparta, NJ 07871

© 2022 PLx Pharma Inc. All rights reserved.